Ann: Phase II study for eftilagimod alpha in COVID-19 advances, page-9

Primary endpoint for each specific patient is 15 days from first dose, however, it is likely (and I HOPE) we will not hear any news till completion of recruitment and after Data Review, which takes place at the end of completion, 15 days after the last patient is dosed.

So, how soon we here the next news all depends at what rate they recruit. If they have 110 patients lined up already then this can be a matter of a few weeks.

But there are various scenarios:

1- Discontinuation due to clear and unacceptable adverse effect. This scenario is unlikely as safety profile for Efti is long established AND also this study has confirmed safety in Covid patients.

2- Discontinuation due to reasonable indication that efficacy (usefulness to treat covid) is questionable at some point before completion. At a guess they have already at least been encouraged by some positive indication in the 6 preliminary patients they have treated and reviewed (likely very thoroughly - as you can see how long it took to complete that phase - since October 20).

3- Completion and Data Review finding the there is no (statistically) significant advantage. Well, at least we will have tried AND we will have more info on efti for viral diseases and safe. So, that will be positive news.

4- Completion and Data Review finding results are statistically significant but not sufficiently significant advantage to warrant considering as a treatment. This scenario is, "We are barking at the right tree in anti-viral venture". Game will be on ...

5-This last scenario is, "Bob is you uncle": Completion and Data Review finds results are statistically significant and continue to Ph IIb or III (depending on level of success) -

So, as you can see, for now, THE BEST news is NO news till completion of recruitment and Data Review.